

Daniel Giroux Joins Advantagene as Vice President, Manufacturing

Auburndale, MA, November 4, 2016 - Advantagene, Inc., a clinical-stage biotechnology company developing a novel cancer immunotherapy platform for the treatment of solid tumors, announced today that Daniel Giroux has joined the company as Vice President, Manufacturing. Mr. Giroux will be primarily responsible for the clinical and commercial production of our proprietary viral vector *aglatimagene besadenovec* (a.k.a. *AdV-tk*) currently undergoing clinical studies in localized prostate cancer, glioblastoma, pediatric glioma, pancreas and lung cancers.

Mr. Giroux brings over 25 years of professional experience in bioprocess development, biopharmaceutical manufacturing and bio-processing equipment design and manufacturing to Advantagene. He is among the country's thought leaders in the manufacture of viral vectors, with particular expertise in adenovirus production and analytical methods, having worked for 11 years at Canji, the gene therapy arm of Schering-Plough Corporation. At Canji he was instrumental in quantifying molecular diffusion in the adenovirus infection process and for the production of purified adenovirus vectors for clinical studies under a California FDB license. More recently, Mr. Giroux was Vice President of Research and Development at PBS Biotech, a manufacturer of single-use bioreactors, where he oversaw the product development of a scalable line of single use bioreactors. Mr. Giroux holds a B.Sc. in Biochemistry and a B.Sc.A in Chemical Engineering, both from the University of Ottawa.

"We are very pleased to welcome Daniel to the Advantagene leadership team," said Dr. Estuardo Aguilar-Cordova, Chief Executive Officer of Advantagene. "Daniel is among the leading executives in the country when it comes to the commercial production of adenoviral vectors. He brings a wealth of scientific and practical experience that we intend to leverage to enable us to optimize our manufacturing processes and to deliver a commercial product suitable for BLA approval and commercial distribution. We continue to drive our GMCI™ product platform toward approval in multiple solid tumor indications and we'll look to Daniel to implement process improvements and a scalable manufacturing strategy suitable to meet our clinical and commercial needs."

About Advantagene, Inc.

Advantagene is a Massachusetts based biotechnology company developing its proprietary Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform technology for the treatment of solid tumors. GMCI™ is an "off the shelf" low toxicity immunotherapy that stimulates a patient's immune system to generate a robust response against his or her individual cancer. The company is conducting clinical studies using its GMCI™ technology in lung, pancreas, prostate and brain cancers with remarkable clinical results to date. Ongoing studies include a registration clinical trial with its lead candidate, ProstAtak®, under a Special Protocol Assessment approved by the U.S. Food and Drug Administration, for the treatment of localized

prostate cancer patients with intermediate to high risk disease choosing radiation therapy. If proven efficacious, ProstAtak® will be the first and only therapeutic pharmaceutical available for newly diagnosed localized prostate cancer patients. For more information about Advantagene and our GMCI™ cancer immunotherapy program please visit www.advantagene.com.

Contact

Media & Investor Relations

Advantagene, Inc.

440 Lexington Avenue

Auburndale, MA 02466

(617) 916-5445

info@advantagene.com

Released November 4, 2016